



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 1st June 2022

Dear Melanie Wilson

Re: Freedom of Information Request 146-2022

Thank you for your email dated the 29th April 2022, requesting information in relation to incidence and treatment of CLL and MCL.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL) – 39 patients**
- **Mantle Cell Lymphoma (MCL) – Exempt under S40**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.**

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- **BR (bendamustine + rituximab) – 0 patients**
- **Calquence (acalabrutinib) – 0 patients**
- **FCR (fludarabine + cyclophosphamide + rituximab) – 0 patients**
- **Gazyva (obinutuzumab) + chlorambucil – 0 patients**
- **Imbruvica (ibrutinib) – 0 patients**
- **Venclexta (venetoclax) – 0 patients**

- Venclexta (venetoclax) + Gazyva (obinutuzumab) – 0 patients
- Venclexta (venetoclax) + rituximab – 0 patients
- Zydelig (idelalisib) + rituximab – 0 patients
- Any other systemic anti-cancer therapy – 0 patients

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- BR (bendamustine + rituximab) – 0 patients
- Imbruvica (ibrutinib) – 22 patients
- Imbruvica (ibrutinib) + rituximab – 0 patients
- R-BAC (rituximab, bendamustine and cytarabine) – 0 patients
- R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) – 0 patients
- Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) – 0 patients
- Velcade (bortezomib) + chemotherapy – 0 patients
- Any other systemic anti-cancer therapy
 - Acalabrutinib – Exempt under S40
 - Rituximab – Exempt under S40
 - Venetoclax – 9 patients
 - Immunoglobulin – Exempt under S40
 - Rituximab + Chlorambucil – Exempt under S40
- Stem cell transplant – 0 patients
- Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells - 0 patients

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

[Chronic Lymphocytic Leukaemia \(CLL\)](#)

Please see attachment relating to question 4

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

[Mantle Cell Lymphoma \(MCL\)](#)

Please see attachment relating to question 5

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY.

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind regards

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net